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SPECIAL SERIES: DISPARITIES IN CANCER CARE FOR BLACK PEOPLE IN THE UNITED STATES
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Cancer Disparities and Black American
Representation in Clinical Trials Leading to the
Approval of Oral Chemotherapy Drugs in the
United States Between 2009 and 2019
Veronica B. Ajewole, PharmD, BCOP1,2,3; Oyinkansola Akindele, PharmD Candidate1; Uzoamaka Abajue, PharmD Candidate1;
Okwuoma Ndulue, PharmD Candidate1; Jazzmin J. Marshall, PharmD Candidate1; and Yhenew T. Mossi, PharmD Candidate1

abstract

PURPOSE Over the past 10 years, oral chemotherapy made up about half (45.6%) of all US Food and Drug Administration (FDA)–approved oncolytic and hematologic medications. Given the disparity in incidence and mortality
rate because of certain cancers among Black Americans (BAs) in the United States, a review of BA’s representation in
the clinical trials that lead to the development and FDA approval of oral chemotherapy drugs becomes imperative.
The objective of this study was to evaluate the reporting of race and inclusion of BA in clinical trials that led to the
approval of oral chemotherapy medications by the FDA from 2009 to 2019 in the United States. Additionally, we
evaluated the inclusion of BAs in clinical trials of three cancer types with the highest disparity rates among BAs (lung,
breast, and prostate).
METHODS A retrospective review of all FDA-approved oral chemotherapy drug from 2009-2019 was obtained
using the FDA’s Hematology/Oncology Approvals & Safety Notiﬁcations website. Reports of racial and demographics inclusion were obtained from the clinical trials registry.
RESULTS Primary outcome: 142 clinical trials led to FDA approval of 81 oral chemotherapy agents between 2009
and 2019, among which 74 (52%) reported on at least one race and were included in our analysis. 35,933
participants were enrolled in these 74 clinical trials, among which 25,684 (71.47%), 6,061 (16.87%), 889
(2.47%), and 826 (2.30%) were White, Asian, Black, and Hispanic, respectively. BAs were also underrepresented in the clinical trials of three cancer types with the highest disparity rates among this population.
CONCLUSION BAs were under-represented in clinical trials leading to FDA approval of oral chemotherapy drugs.
There should be more BAs in cancer clinical trials to increase the generalizability of the results, improve
outcomes, and eventually close the health disparity gap among this patient population.
JCO Oncol Pract 17:e623-e628. © 2021 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
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Oral chemotherapy agents have become more prevalent in treating various cancers. Between March 2009
and December 2019, the US Food and Drug Administration (FDA) approved 81 oral chemotherapy
agents with some oral chemotherapy agents having
multiple indicatons.1 The increased occurrence of oral
chemotherapy usage has been attributed to ease of
administration and improved quality of life.2 Although
many oral chemotherapy agents have been approved
by the FDA, patient populations from diverse racialethnic background inclusive of the US population are
often not adequately represented or reported in clinical
trials,3 thus leading to racial disparity among oncology
patient representation in clinical trials.3 According to

Healthy People 2020, health disparity is a health
difference that is intricately linked with social, economic, and/or environmental disadvantage.4 Racial
disparities in health care can have a signiﬁcant impact
on patient outcomes and survival.5 According to the
National Institutes of Health (NIH), health disparity
populations include Black or African American,
Hispanic or Latino, American Indian or Alaska Native,
Asian American, Native Hawaiian, and other Paciﬁc
Islander.6 Ethnic minorities, particularly Black Americans (BAs), have higher incidence for many
cancers such as lung, prostate, and colon, which
occur in 62.4, 173.0, and 45.7 BAs per 100,000
people, compared with 63.5, 97.1, and 38.6 White per
100,000 people, respectively.5,7 Unfortunately, BAs
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also have higher mortality rates in cancers such as prostate,
where mortality rates are more than double any other racial
group.7 More speciﬁcally, among BAs, mortality rates for
lung, prostate, and colon cancers are 43.5, 38.7, and 19
per 100,000 people, respectively, whereas mortality rates
among White are 43.4, 18, and 13.8, respectively.7 Although the incidence of breast cancer is lower in BAs
compared with White (126.7 v 130.8 per 100,000 people),
breast cancer causes signiﬁcantly higher mortality in BAs
compared with White (28.4 v 20.3 per 100,000 people).7
Lung and colon cancers are the second and third most
common cancers after prostate cancer in men and breast
cancer in women.7 Many clinical trials focus on representing the demographics of the United States without
considering the increased cancer burden in BAs.8 Although
cancer rates are higher among BAs, BAs in clinical trials
remain low.3 This poses a challenge because genetic
variation among ethnic minority groups can be a determinant of health outcomes.3
In 1993, the NIH Revitalization Act was passed by US
congress to lead the federal agency’s inclusion of women
and ethnic minorities in clinical studies to promote clinical
research equity.9 As a result, over the past 27 years, gender
participation has leveled off with 72% female participation
in clinical trials in 2019.10 However, clinical trials continue
to lack racial and ethnic diversity. As of 2019, BAs
accounted for 13.4% of the total US population and only
9% participated in clinical trials, whereas White represented 76.5% of the US population and 72% participated
in clinical trials.10,11
Understanding the safety and efﬁcacy of drugs for all patients hinges on the participation of diverse racial and
ethnic subgroups. When drugs are tested in clinical trials, it
is believed that the population that the drug was tested in
mirrors the patient population who will ultimately receive
treatment with the drug. When there is skewing in the
clinical trial population relative to the population of patients
that actually receive the drug, extrapolation of clinical
outcomes across all patient population becomes very
challenging. This disproportionate participation of BAs in
clinical research limits the ability of BAs to fully beneﬁt
from biomedical research advances (including access
to cutting-edge therapies) and contributes to racial health
disparities.12-14 Clinical trials with diverse populations
are needed to better predict the generalizability of clinical
outcomes among minority population.5 Although the
NIH has placed regulations that require minority representation in clinical trials, enrollment in clinical trials remains disproportional to prevalence of disease among
BAs.3,5
Awareness of the current trend of cancer disparities and BA
representation in clinical trials leading to the approval of
oral chemotherapy drugs in the United States becomes
imperative. This will inform stakeholders, policymakers,
health ofﬁcials, and the general public in informed decision

making that will enhance BA participation and representation in oral chemotherapy clinical trials. This will be a step
in the right direction to closing the health disparity gap in
cancer care for BAs. Thus, in this paper, we present our
review of clinical trial enrollment demographics for FDAapproved oral chemotherapy medications between 2009
and 2019.
METHODS
Study Cohort
We retrospectively reviewed all oral chemotherapy drugs
approved by the FDA from March 2009 to December 2019
using the FDA’s Hematology/Oncology (Cancer) Approvals
& Safety Notiﬁcations website.1 We identiﬁed the four major
races based on US census categories.11 Race reporting was
obtained from the NIH clinical trials registry,15 and also
reconciled with the published primary literature for each
drug. The data from the NIH clinical trials registry15 and
published primary literature were also reviewed to identify if
the clinical trials enrolled patients predominantly in the
United States, International counties including the US,
or Non-US–based countries. Based on available literature,
we identiﬁed trials where there is a known racial subset that
would be over-represented because of disease prevalence
among certain racial-ethnic population. Additionally, information about industry-sponsored versus cooperative
group trials was collected. For drug approvals with
more than one clinical trial, we included all trials in our
analysis. Data on the US cancer incidence and mortality
were obtained from National Cancer Institute’s SEER
database.16
Statistical Analysis
Of the clinical trials obtained, trials that did not report on at
least one race were ﬁltered out. Of the remaining trials, the
total number of participants enrolled in each clinical trial
was used to calculate the proportion of White, Asian, Black,
and Hispanic enrolled in each clinical trial, which is the
primary outcome of our study.
The clinical trials data were further analyzed by cancer type
with highest mortality in BA population—Lung, Breast, and
Prostate Cancer. Although colorectal cancer has a high
mortality rate among BA population, the three clinical trials
on colorectal cancer did not report racial demographics
and thus were excluded from our analysis. Based on these
data, the total number of participants enrolled in each
clinical trial was used to calculate the proportion of White,
Asian, Black, and Hispanic enrolled in each clinical trial.
This composite analysis is the secondary outcome for this
study. Additionally, we report on clinical trials patients’
enrollment locations as predominantly United States, International counties including the United States, or NonUS–based countries as well as racial subset enrollment
because of disease prevalence among certain racial-ethnic
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population and industry-sponsored versus cooperative
group trials.
RESULTS
Primary Outcome
One hundred forty-two clinical trials led to FDA approval of
81 oral chemotherapy drugs in the United States between
2009 and 2019. Among these 142 clinical trials, 74 (52%)
of these reported on at least one race and were included in
our analysis. A total of 35,933 participants were enrolled in
these 74 clinical trials. Among the 35,933 participants,
25,684 (71.47%), 6,061 (16.87%), 889 (2.47%), and 826
(2.30%) were White, Asian, Black, and Hispanic, respectively. See Figure 1 for details.
Secondary Outcomes
Non–small-cell lung cancer. Between 2009 and 2019, 21
clinical trials led to FDA approval of 12 oral chemotherapy
agents for the treatment of non–small-cell lung cancer.
Among these 21 clinical trials, 11 (52%) reported on at
least one race and were included in our analysis. These 11
clinical trials had a total of 3,811 participants enrolled with
1,605 (42.11%), 2,125 (55.75%), 43 (1.12%), and 39
(1.02%) being White, Asian, Black and Hispanic, respectively. See Figure 2 for details.
Breast cancer. Between 2009 and 2019, 12 clinical trials
led to FDA approval of 11 oral chemotherapy agents for the
treatment of breast cancer. Among these 12 clinical trials,
eight (66.67%) reported on at least one race and were
included in our analysis These eight clinical trials enrolled
7,318 participants with 5,540 (75.70%), 1,136 (15.52%),
154 (2.10%), and 273 (3.73%) being White, Asian, Black,
and Hispanic, respectively. See Figure 2 for details.
Prostate cancer. Between 2009 and 2019, eight clinical
trials led to FDA approval of six oral chemotherapy agents

2.47%

2.33%

16.87%

White
Asian
Black
Hispanic

71.47%

FIG 1. Black American representation in oral chemotherapy clinical
trials, 2009-2019.

for the treatment of prostate cancer. Among these eight
clinical trials, six (75%) reported on at least one race and
were included in our analysis These six trials enrolled 6,876
participants with 5,022 (73.04%), 805 (11.71%), 225
(3.27%), and 154 (2.24%) being White, Asian, Black, and
Hispanic, respectively. See Figure 2 for details.
Other Outcomes
Clinical trials patients’ enrollment location. Among all 142
clinical trials, 26 (18%) clinical trials enrolled patients
predominantly in the United States. Of these 26 clinical
trials, 14 (54%) reported on at least one race. Of these 14
clinical trials, the enrollment rate of White, Asian, Black,
and Hispanic ranged from 38.4%-94.8%, 1.8%-30%,
0.52%-7.1%, and 2.2%-8.9%, respectively. Among all 142
clinical trials, 106 (75%) enrolled patients across international counties including the United States. Of these 106
clinical trials, 56 (52.8%) reported on at least one race. Of
these 56 clinical trials, the enrollment rate of White, Asian,
Black, and Hispanic ranged from 31.9%-98.7%, 0.6%65.4%, 0.18%-3.2%, and 0.93%-17.2%, respectively.
Among all 142 clinical trials, 10 (7%) enrolled patients in
Non-US–based countries. Of the 10 clinical trials, 6 (60%)
reported on at least one race. Of these six clinical trials, the
enrollment rate of White, Asian, Black, and Hispanic
ranged from 23.2%-78.4%, 13.6%-42%, 0.2%-5.2%, and
9.4%-12.1% respectively.
Racial subset enrollment because of disease prevalence
among certain racial-ethnic population. Among all 142
clinical trials, nine (6%) were inﬂuenced by disease
prevalence among certain racial-ethnic population mostly
because of epidermal growth factor receptor–activating
mutations and Asian populations in lung cancer. Among
these nine clinical trials, 5 (55.6%) reported on at least one
race. Of these ﬁve clinical trials, the enrollment rate of
White, Asian, Black, and Hispanic ranged from 23.2%62.4%, 62.4%-76.5%, 0.2%-1.4%, and 1.9% – 2.5%,
respectively.
Industry-sponsored versus cooperative group trials. Among
all 142 clinical trials, 136 (95.8%) were industry sponsored,
3 (2.1%) were cooperative group trials, whereas 3 (2.1%)
were sponsored by other entities like National Cancer Institute, NCI. Of the 136 industry-sponsored trials, 71
(52.2%) reported on at least one race. Of these 71 clinical
trials, the enrollment rate of White, Asian, Black, and
Hispanic ranged from 31.9%-98.7%, 0.6%-65.4%,
0.18%-7.1%, and 0.93%-17.2%, respectively. Of the three
cooperative group trials, 2 (66.7%) reported on at least one
race, whereas of the three other sponsored trials, 1 (33.3%)
reported on at least one race.
DISCUSSION
During the 10-year time frame of our analysis (2009-2019),
racial reporting in clinical trials leading to the approval of
oral chemotherapy drug was identiﬁed in only about half of
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FIG 2. Black American inclusion in oral chemotherapy clinical trials involving top three disparity-related cancers
among Black American populations 2009-2019.

these clinical trials. The representation of BAs was consistently low relative to the cancer burden among this
population. There was low representation of BAs remained
consistently low regardless of enrollment locations and
industry-sponsored versus cooperative group clinical trials.
Asian people were more reasonably represented in clinical
trials for tumors with EGFR activating mutations that can be
more prevalent in locations with larger Asian populations.
Regardless of enrollment locations, clinical trial sponsorship, or disease prevalence among certain racial-ethnic
population, these medications are FDA approved in the
United States for use of general population including BAs.
This ﬁnding calls for more efforts to be made for reporting
of racial representation in clinical trials as this will lead to
better generalizability of study ﬁndings.

system as a barrier to participation in cancer-related clinical
trials.17 Understanding these factors is critical for rectifying
the disparities shown in our analysis. Lack of diversity in
clinical trials decreases opportunities for identifying effects
that could be particularly important to ethnic minority
populations, thus leading to inappropriate distribution of
beneﬁts and risks of clinical trial participation.17 Increasing
BA participation in clinical trials will lead to results that are
generalizable to patients treated with the approved agents
and higher quality of care for all patients.

Several factors that affect BA participation in cancer-related
clinical trials have been identiﬁed.17 For example, BAs are
most likely to complain of mistrust of research and medical

In conclusion, BAs are under-represented in oral chemotherapy oncology clinical trials despite efforts made to increase minority participation in clinical trials. Considering
the higher mortality rate found in this population in certain
cancer types, there should be more BAs in cancer clinical
trials to increase the generalizability of the results, improve
outcomes, and eventually close the health disparity gap
among this patient population.
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